At Theranostics Australia, we pride ourselves in offering both contemporary and innovative treatment options for patients in the form of theranostics, a personalised approach to cancer medicine. We have offered integrated molecular imaging and targeted radiopeptide therapies for various tumour types since 2015, at our treatment facility located at Ramsay Hollywood Hospital, Perth, WA. Since April 2017, we have been able to also offer these therapies at Macquarie University Hospital, Sydney, NSW.
As the first private theranostics provider in Australia, our aim is to continuously develop and utilise targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers. We have a particular focus on cancers which are difficult to treat or are becoming resistant to conventional therapies.
In May 2015 Theranostics Australia was established by Dr Nat Lenzo who wanted to provide patients with contemporary cancer treatment options. Since 1999 he has been involved with treatment of thyroid cancer with radioactive iodine and new agents such as I-131 rituximab for lymphoma treatment and Lu-177 octreotate for neuroendocrine tumour treatment. The company commenced in Perth, Western Australia and the head office is based in East Fremantle. The medical facilities are housed in the premises of Diagnostic Nuclear Imaging at Hollywood Private Hospital (WA) and Macquarie Medical Imaging at Macquarie University Hospital (NSW).
Diagnostic Nuclear Imaging, headed by Dr Joe Cardaci has a long history of involvement in radionuclide therapies. They are one of the pioneers in developing SIRT therapy for metastatic tumours to the liver and provide this service at Hollywood Private Hospital. They are also the first practice in Western Australia to administer Radium-223 for metastatic bone disease from prostate cancer.
To develop and provide powerful and innovative therapies.
To improve quality of life and restore hope.
Courage, Education, Excellence, Hope and Innovation.